Meet ERS Assembly 5: airway diseases http://ow.ly/M4ou306WbrQ
Assembly 5 brings together numerous specialists in the field of chronic airway diseases. Not only clinicians, researchers and therapists, but also students interested in asthma, chronic obstructive pulmonary disease (COPD) and cough. These are diseases with high and rising prevalence despite the availability of good therapeutic interventions. They have high associated morbidity, mortality and socioeconomic costs. The Assembly now has more than 1000 members, active in three main groups: 5.1) airway pharmacology and treatment, with the aim to discover new drugs for asthma, COPD and cough, and to translate the results of basic science into clinical development; 5.2) monitoring airway diseases, with the aim to evaluate new methodologies, biomarkers and parameters useful to monitor airway diseases; and 5.3) allergy and immunology, with the aim to study mechanisms at the basis of asthma and COPD. The expertise gathered in this Assembly favours the interaction between basic and clinical studies, offering new opportunities to improve diagnostic processes and personalised therapies. The concept of stratified or personalised medicine in airway disease has been driven by members of Assembly 5 and is an increasing priority amongst all groups.